ALFA Finder India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold Telegram alerts alfafinder.com →
Saturday, 14 November 2026 Every NSE & BSE announcement, by company
ALFA Filings Every announcement, straight from the exchange
Earnings Call

Influx Healthtech Earnings Call: Key Takeaways

Influx Healthtech reported FY26 revenue of ₹146cr, a 41% YoY increase, with PAT at ₹20.5cr. Strategy focuses on scaling nutraceutical CDMO capacity by 2.5x through a new 75,000 sq ft facility.

Highlights
Revenue growth41% YoY in FY26.
MarginsEBITDA margin 20.3%; PAT margin 14%; target 20-22% EBITDA for FY27.
Order book718+ clients; 98% retention rate; new orders for Quick Snap format.
Demand visibilityStrong visibility in nutraceuticals driving facility expansion.
Management confidenceHigh; confident in maintaining 14% PAT margins.

Growth

FY26 Revenue up 41% to ₹146cr; EBITDA up 32% to ₹29.9cr; PAT grew to ₹20.5cr (14% margin).

Outlook

Guidance of 25-30% minimum growth for FY27; long-term target of ₹500cr revenue by FY29.

Risks

Raw material price volatility in solvents/packaging and potential lag in passing costs to customers.

Source

Earnings Call filed with NSE, NSE: INFLUX. Summary written with AI assistance from the document.

Read the document ↗

Influx Healthtech Ltd: key numbers

Share price
₹280.25
Market cap
₹648.8 Cr
Revenue (annual)
₹146.8 Cr
Net profit (annual)
₹20.54 Cr
P/E (TTM)
31.6×Sector 43.7×
Promoter holding
73.53%
FII holding
0.41%Current quarter

Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.

More from Influx Healthtech Ltd

All →